Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00329069
Status:
COMPLETED
Last Update Posted:
2006-05-24
First Post:
2006-05-22
Brief Title:
The Role of Atorvastatin on Monocyte Function in Patients With Coronary Artery Disease and Hypercholesterolemia
Sponsor:
University of Ulm
Organization:
University of Ulm
Study Overview
Official Title:
Vascular Endothelial Receptor Activity in Patients With Coronary Artery Disease on Medication With Statins
Status:
COMPLETED
Status Verified Date:
2006-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to determine whether an intensified atorvastatin therapy can improve monocyte function in patients with coronary artery disease and hypercholesterolemia
Detailed Description:
Hypercholesterolemia is one of the most important cardiovascular risk factors that significantly elevates the risk for the development and progression of arteriosclerotic diseases
Statins such as atorvastatin have been shown to reduce atherogenic lipoprotein levels as well as cardiovascular morbidity and mortality in a large number of clinical trials It is suggested that statins have- apart from their lipid-lowering properties- other pleiotropic effects that are responsible for their anti-atheroslerotic and and cardioprotective potential
Monocytes are crucially involved in the process of arteriogenesis ie the growth of preexisting arterioles Monocyte chemotaxis can be stimulated with arteriogenic molecules such as vascular endothelial growth factor A VEGF-A In previous studies we could demonstrate that the VEGF-A- induced monocyte chemotaxis is severely impaired in hypercholesterolemic patients This reduced response to VEGF seems to be associated with a decreased ability to form functional collaterals
Therefore we hypothesize that an intensified therapy with atorvastatin 40 mg once a day can significantly improve monocyte function in patients with coronary artery disease and hypercholesterolemia compared to patients who are only treated with a placebo
Statins such as atorvastatin have been shown to reduce atherogenic lipoprotein levels as well as cardiovascular morbidity and mortality in a large number of clinical trials It is suggested that statins have- apart from their lipid-lowering properties- other pleiotropic effects that are responsible for their anti-atheroslerotic and and cardioprotective potential
Monocytes are crucially involved in the process of arteriogenesis ie the growth of preexisting arterioles Monocyte chemotaxis can be stimulated with arteriogenic molecules such as vascular endothelial growth factor A VEGF-A In previous studies we could demonstrate that the VEGF-A- induced monocyte chemotaxis is severely impaired in hypercholesterolemic patients This reduced response to VEGF seems to be associated with a decreased ability to form functional collaterals
Therefore we hypothesize that an intensified therapy with atorvastatin 40 mg once a day can significantly improve monocyte function in patients with coronary artery disease and hypercholesterolemia compared to patients who are only treated with a placebo
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None